Advertisement

 

 

Radiotherapy of nasopharyngeal cancer using Rapidarc: dosimetric study of military teaching hospital Mohamed V, Morocco.

Radiotherapy of nasopharyngeal cancer using Rapidarc: dosimetric study of military teaching hospital Mohamed V, Morocco.
Author Information (click to view)

Lalya I, Marnouche EA, Abdelhak M, Zaghba N, Andaloussi K, Elmarjany M, Baddouh L, Dahmani K, Hadadi K, Sifat H, Mansouri H,


Lalya I, Marnouche EA, Abdelhak M, Zaghba N, Andaloussi K, Elmarjany M, Baddouh L, Dahmani K, Hadadi K, Sifat H, Mansouri H, (click to view)

Lalya I, Marnouche EA, Abdelhak M, Zaghba N, Andaloussi K, Elmarjany M, Baddouh L, Dahmani K, Hadadi K, Sifat H, Mansouri H,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

BMC research notes 2017 02 2810(1) 112 doi 10.1186/s13104-017-2430-2
Abstract
BACKGROUND
The aim of the present study is to assess efficacy and efficiency of Volumetric-modulated arc therapy (VMAT) technique in treatment of nasopharyngeal cancer in our institution and to report toxicity related to this technique.

METHODS
Between June 2013 and January 2015, thirty-two patients with non metastatic nasopharyngeal cancer were curatively treated using VMAT Rapidarc. Dose prescription was performed using two different schedules, it consisted of either simultaneous integrated boost or simultaneous modulated accelerated radiation therapy delivering 70 Gy in 35 fractions and 69.96 in 33 fractions respectively. The choice was leaved at the discretion of the treating physician. The optimization process was performed by Eclipse software version 10.0 (Varian Medical Systems), using PRO algorithm (Progressive resolutive optimisation) version 3. Data was collected from dose-volume histograms for both planning target volumes (PTV) and organs at risk (OAR). We calculated the homogeneity index and the conformity index as well as the number of monitor units MU and the treatment delivery time. We also reported acute and late toxicity related to radiation therapy.

RESULTS
For the PTV high risk (HR), intermediate risk (PTV IR) and low risk (LR) the D95% was 97.21 ± 1.5, 97.5 ± 3.3 and 97.10 ± 6.86 respectively. Whereas, The D5% was 104.6 ± 2.16, 103.8 ± 2.1 and 100.89 ± 7.26. The CI for PTV HR was 0.98 ± 0.02 and the HI was 0.08 ± 0.02. The mean treatment delivery time was 2.3 ± 0.2, and the mean MU number was 527.6 ± 131.4. Grade 4 toxicity was not reported in any case. Grade 3 xerostomia was observed in only 3(9.4%) patients and no patients developed grade 3 hearing loss.

CONCLUSION
Our results confirmed the abilities of VMAT to provide excellent coverage of target volumes while sparing OAR especially the nervous structures and salivary glands.

Submit a Comment

Your email address will not be published. Required fields are marked *

two × 1 =

[ HIDE/SHOW ]